logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
R

Ruben A. Mesa

wake forest baptist medical center

96H指数
1.3K论文数
4.5W被引数
收录论文 221
发表时间
logo
Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis输血状态、血红蛋白水平与骨髓纤维化患者报告结局的相关性：一项事后临床 trial 分析
errCancer Medicine
IF3.1
err2026-04-10
err0
errOAAI
errRuben Mesa; Jeanne M. Palmer; Francesca Palandri; Lucia Masarova; Claire N. Harrison; Flora Mazerolle; Manal M'hari; Tom Liu; Shiyuan Zhang; Anna Cardellino; Zhaohui Wang; Catherine E. Ellis; Dwaipayan Patnaik; Antoine Regnault; Thomas W. LeBlanc
err分享
err收藏
Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemia鲁索利替尼和莫美替尼在骨髓纤维化伴贫血患者中的药房和输血成本
errLEUKEMIA & LYMPHOMA
IF2.2
err2026-01-01
err0
PREAI
errGerds, Aaron T.; Yu, Jingbo; Tao, Charles; Carlton, Rashad; Naim, Ahmad B.; Mesa, Ruben A.
err分享
err收藏
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis欧洲白血病网络联盟（European LeukemiaNet）关于新药在骨髓纤维化中安全性和有效性评估的标准
errBlood Cancer Journal
IF11.6
err2025-11-24
err0
errOAAI
errMonia Marchetti; Alessandro Maria Vannucchi; John O. Mascarenhas; Alberto Alvarez-Larran; Prithviraj Bose; Robert Peter Gale; Claire Harrison; Rűdiger Hehlmann; Jean-Jacques Kiladjian; Steffen Koschmieder; Ruben Mesa; Francesco Passamonti; Alessandro Rambaldi; Ayalew Tefferi; Tiziano Barbui
err分享
err收藏
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study罗培干扰素alfa-2b在羟基脲不耐受或羟基脲难治性原发性血小板增多症（SURPASS ET）：一项多中心、开放标签、随机、活性对照、III期研究
errThe Lancet Haematology
IF0
err2025-11-03
err0
PREAI
errRuben Mesa; Harinder Gill; Lei Zhang; Jie Jin; Keita Kirito; Norio Komatsu; Albert Qin; Zhijian Xiao; Tsewang Tashi; Kazuya Shimoda; Kohshi Ohishi; Suning Chen; Xuelan Zuo; Shuichi Shirane; Yu Hu; Sujiang Zhang; Yi Wang; Katsuto Takenaka; Michiko Ichii; Na Xu; Lee-Yung Shih; Ken-Hong Lim; Sung-Eun Lee; Sung Hwa Bae; Winnie Z Y Teo; Dawn Maze; Stephen T Oh; Prithviraj Bose; Toshiaki Sato; Oleh Zagrijtschuk; Sheena Lin; Weichung Joe Shih; John Mascarenhas; Lucia Masarova
err分享
err收藏
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative NeoplasmsMPN Asia 2025亮点：髓系增殖性肿瘤的分子发病机制和治疗策略进展
errCurrent Hematologic Malignancy Reports
IF3.3
err2025-07-12
err0
errOAAI
errPrithviraj Bose; Zhijian Xiao; Hans C. Hasselbalch; Josef T. Prchal; Minghui Duan; Abdulraheem Yacoub; Raajit Rampal; Jean-Jacques Kiladjian; Gabriela S. Hobbs; Tsewang Tashi; Kazuya Shimoda; Keita Kirito; Harinder Gill; Hsin-An Hou; Sung-Eun Lee; Jian Huang; Bing Li; Albert Qin; Lennex Hsueh-Lin Yu; John O. Mascarenhas; Ruben A. Mesa
err分享
err收藏
A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database使用FDA不良事件报告系统（FAERS）数据库进行的真性红细胞增多症治疗相关不良事件药物警戒研究
errAnnals of Hematology
IF2.4
err2025-07-10
err0
errOAAI
errBrandi N. Reeves; Lucia Masarova; Ghaith Abu-Zeinah; Anthony M. Hunter; Joseph J. Shatzel; Albert Qin; Chang Ho Yoon; Ling-Yu Cai; Yu-Feng Wei; Ruben A. Mesa
err分享
err收藏
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study患者报告结局和医疗提供者对系统性肥大细胞增多症的认知：PRISM研究的结果
errclinical and experimental allergy
IF0
err2025-06-27
err0
PREAI
errMassimo Triggiani; Jessica Hobart; Iván Alvarez-Twose; Cristina Bulai Livideanu; Franziska Ruëff; Stéphane Barete; Patrizia Bonadonna; Laurence Bouillet; Nauman M. Butt; Mark Drummond; Mar Guilarte; Karin Hartmann; Amélie Beaux; Celeste C. Finnerty; Nicole Hegmann; Patrizia Marcis; Eugenia Ribada; Waltraud Schinhofen; Gabriela Coletti; Andrew Dugdale; Cristian Perez; Dakota Powell; Teresa Green; Erin Sullivan; Deepti H. Radia; Ruben Mesa
err分享
err收藏
The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation金融毒性肿瘤委员会: 5年实践更新和实施指南
errJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
IF16.4
err2025-05-01
err1
PREAI
errKnight, Thomas G.; Hensel, Caitlin; Blackley, Kris; Wheeler, Mellisa; Warden, Hughes R.; Turan, Wendy Jo; Moroe, Jaynie; Chai, Seungjean; Feild, Donna; Mesa, Ruben; Raghavan, Derek
err分享
err收藏
Polycythaemia vera
errNature Reviews Disease Primers
IF60.6
err2025-04-17
err0
PREAI
errHarrison, Claire N.; Barbui, Tiziano; Bose, Prithviraj; Kiladjian, Jean-Jacques; Mascarenhas, John; McMullin, Mary Frances; Mesa, Ruben; Vannucchi, Alessandro M.
err分享
err收藏
Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b
errANNALS OF HEMATOLOGY
IF2.4
err2025-04-01
err0
errOAAI
errMesa, Ruben; Yacoub, Abdulraheem; Tashi, Tsewang; Chai-Ho, Wanxing; Yoon, Chang Ho; Mascarenhas, John
err分享
err收藏
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialPelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化：一项随机III期试验
errNATURE MEDICINE
IF50
err2025-03-10
err2
errOAAI
errRampal, Raajit K.; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T.; Vannucchi, Alessandro M.; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T.; Kuykendall, Andrew T.; Patriarca, Andrea; alvarez-Larran, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M.; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N.; Mascarenhas, John
err分享
err收藏
Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms最近的翻译和治疗进展对BCR临床过程的影响::ABL1-Positive和阴性骨髓增殖性肿瘤
errHEMATOLOGICAL ONCOLOGY
IF3.9
err2025-01-18
err0
PREAI
errMughal, Tariq I.; Mascarenhas, John; Rampal, Raajit K.; Bose, Prithviraj; Lion, Thomas; Ajufo, Helen; Yacoub, Abdulraheem; Meshinchi, Soheil; Masarova, Lucia; Mesa, Ruben; Jamieson, Catriona; Barbui, Tiziano; Saglio, Giuseppe; Van Etten, Richard A.
err分享
err收藏
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
errANNALS OF HEMATOLOGY
IF2.4
err2025-01-13
err0
errOAAI
errYacoub, Abdulraheem; Abu-Zeinah, Ghaith; Qin, Albert; Tashi, Tsewang; Da'na, Waleed; Shih, Weichung Joe; Zagrijtschuk, Oleh; Tsai, Chan-Yen; Geller, Robert; Komatsu, Norio; Mesa, Ruben; Gill, Harinder
err分享
err收藏
National Cancer Institute comprehensive cancer centers: Significant improvement in mortality and symptom control, further opportunities remain toward health equity
errCANCER
IF5.1
err2025-01-02
err0
PREAI
errBarrett, Nadine; Mesa, Ruben
err分享
err收藏
Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study
errQUALITY OF LIFE RESEARCH
IF2.7
err2024-11-25
err2
errOAAI
errDaskalopoulou, Christina; Gorsh, Boris; Dumi, Gerasimos; Deheshi, Samineh; Gwaltney, Chad; Paty, Jean; Ellis, Catherine; Kawashima, Jun; Mesa, Ruben
err分享
err收藏
Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 TrialsFedratinib治疗的FREEDOM和FREEDOM2试验中患者的肾脏健康生物标志物
errBLOOD
IF23.1
err2024-11-05
err1
PREAI
errGupta, Vikas; Chen, Yizhe; Brown, Patrick; Jeyaraju, Danny; Talpaz, Moshe; Mesa, Ruben; Pilot, Richard; Hernandez, Christopher; Wang, Jia; Kiladjian, Jean-Jacques; Vannucchi, Alessandro; Harrison, Claire
err分享
err收藏
Cost Comparison of Ruxolitinib and Momelotinib in Patients with Myelofibrosis and Anemia鲁索利替尼和莫美替尼在骨髓纤维化伴贫血患者中的成本比较
errBLOOD
IF23.1
err2024-11-05
err0
PREAI
errGerds, Aaron T.; Yu, Jingbo; Tao, Charles; Carlton, Rashad; Braunstein, Evan M.; Mesa, Ruben A.
err分享
err收藏
HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary MyelofibrosisHOPE-PMF：一项随机、双盲、安慰剂对照的3期研究，旨在评估罗培干扰素α-2b在早期/低风险原发性骨髓纤维化患者中的有效性和安全性
errBLOOD
IF23.1
err2024-11-05
err0
PREAI
errAbu-Zeinah, Ghaith; Qin, Albert; Gill, Harinder; Komatsu, Norio; Mascarenhas, John O.; Shih, Weichung Joe; Zagrijtschuk, Oleh; Sato, Toshiaki; Shimoda, Kazuya; Silver, Richard T.; Mesa, Ruben A.
err分享
err收藏
A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)一项多中心、开放标签、I期临床试验，评估AJ1-11095以口服单药疗法给药在曾接受过I型JAK2抑制剂（JAK2i）治疗失败的原发性骨髓纤维化（PMF）、真性红细胞增多症后骨髓纤维化（PPV-MF）或原发性血小板增多症后骨髓纤维化（PET-MF）患者中的疗效。
errBLOOD
IF23.1
err2024-11-05
err0
PREAI
errMascarenhas, John O.; Borate, Uma; Bose, Prithviraj; Byrd, John C.; Garcia, Jacqueline S.; Grunwald, Michael R.; Hobbs, Gabriela S.; Hoffman, Ronald; Kuykendall, Andrew T.; Mesa, Ruben A.; Oh, Stephen; Rampal, Raajit; Yacoub, Abdulraheem; Steensma, David P.
err分享
err收藏
Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naive Patients with Myelofibrosis佩拉布雷昔布与鲁索利替尼联合治疗Janus激酶抑制剂初治骨髓纤维化患者的III期Manifest-2研究最新结果
errBLOOD
IF23.1
err2024-11-05
err2
PREAI
errMascarenhas, John O.; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T.; Vannucchi, Alessandro M.; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen; Kuykendall, Andrew T.; Patriarca, Andrea; Alvarez-Larran, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire; Rampal, Raajit
err分享
err收藏

研究方向

暂无研究方向
合作学者
合作期刊
H
Hagop M. Kantarjian
H 指数: 230 · 论文数: 5.5K
J
Jörge E. Cortes
H 指数: 179 · 论文数: 3.6K
T
Tomas Ganz
H 指数: 154 · 论文数: 700
A
Ayalew Tefferi
H 指数: 152 · 论文数: 2.1K
T
Toni K. Choueiri
H 指数: 149 · 论文数: 2.4K
查看更多